1. Repositório Institucional da UFMG
2. Publicações Científicas e Culturais
3. Artigo de Periódico

Type:	Artigo de Periódico
Title:	Ocular inflammatory events following COVID-19 vaccination: a multinational case series
Authors:	Ilaria Testi Carl Herbort Luca Cimino Salam Iriqat Jennifer e. Thorne Jose Echegaray Kalpana Babu Alexander Arthur Bialasiewicz Debra a. Goldstein Nima Ghadiri Alex Fonollosa Calduch Camilo Brandão-de-resende Gabriel Costa de Andrade Padmamalini Mahendradas Julio j. González-lópez Ester Carreño Rola n. Hamam Nicole Stübiger Bahram Bodaghi Yu-jang Chao Masaru Takeuchi Mei-ling Tay-kearney Rupesh Agrawal Alejandro Portero Hiroshi Keino Mar Esteban-ortega Joanna Prze'dziecka-do'yk Aleksandra Radosavljevi' Ian Paredes ho su Ling Wei Kiong Melissa Tien Carlos Pavesio Xin le ng Soon Phaik Chee Jay Siak Ines Hernanz-rodriguez Victor Menezo Christoph Tappeiner Franz Marie Cruz Peter Addison Laura Steeples Robert Kuijpers Daniel Vítor de Vasconcelos Santos Balini Balasubramaniam Peter Mccluskey Francesco Pichi Aniruddha Agarwal
Abstract:	Background Inflammatory adverse events following COVID-19 vaccination are being reported amidst the growing concerns regarding vaccine’s immunogenicity and safety, especially in patients with pre-existing inflammatory conditions. Methods Multinational case series of patients diagnosed with an ocular inflammatory event within 14 days following COVID-19 vaccination collected from 40 centres over a 3 month period in 2021. Results Seventy patients presented with ocular inflammatory events within 14 days following COVID-19 vaccination. The mean age was 51 years (range, 19–84 years). The most common events were anterior uveitis (n = 41, 58.6%), followed by posterior uveitis (n = 9, 12.9%) and scleritis (n = 7, 10.0%). The mean time to event was 5 days and 6 days (range, 1–14 days) after the first and second dose of vaccine, respectively. Among all patients, 36 (54.1%) had a previous history of ocular inflammatory event. Most patients (n = 48, 68.6%) were managed with topical corticosteroids. Final vision was not affected in 65 (92.9%), whereas 2 (2.9%) and 3 (4.3%) had reduction in visual acuity reduced by ≤3 lines and > 3 lines, respectively. Reported complications included nummular corneal lesions (n = 1, 1.4%), cystoid macular oedema (n = 2, 2.9%) and macular scarring (n = 2, 2.9%). Conclusion Ocular inflammatory events may occur after COVID-19 vaccination. The findings are based on a temporal association that does not prove causality. Even in the possibility of a causal association, most of the events were mild and had a good visual outcome.
Subject:	COVID-19 Vacinação SARS-CoV-2 Inflamação Uveíte
language:	eng
metadata.dc.publisher.country:	Brasil
Publisher:	Universidade Federal de Minas Gerais
Publisher Initials:	UFMG
metadata.dc.publisher.department:	MED - DEPARTAMENTO DE OFTALMOLOGIA E OTORRINOLARINGOLOGIA MEDICINA - FACULDADE DE MEDICINA
Rights:	Acesso Aberto
metadata.dc.identifier.doi:	https://doi.org/10.1186/s12348-021-00275-x
URI:	http://hdl.handle.net/1843/61800
Issue Date:	2022
metadata.dc.url.externa:	https://joii-journal.springeropen.com/articles/10.1186/s12348-021-00275-x
metadata.dc.relation.ispartof:	Journal of Ophthalmic Inflammation and Infection
Appears in Collections:	Artigo de Periódico

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.